Company News

PharmaJet to present latest Research Results at World Vaccine & Immunotherapy Congress

GOLDEN, Colo. — November 27, 2018 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced plans to present their latest re-search results at the World Vaccine & Immunotherapy Congress on November 29 at the Loews Coronado Bay Resort in San Diego, California. The presentation, entitled Expanding Vaccine Effectiveness with Needle-free Delivery, will be presented by Dr. Erin Spiegel, Director of Scientific Affairs at PharmaJet, Inc.

Details

PharmaJet and Mundipharma partner to expand access to needle-free technology in emerging markets

SINGAPORE — July 25, 2018 — PharmaJet^® the maker of innovative, needle-free injection technology, and Mundipharma, today announced an exclusive partnership for the multinational healthcare organization to market and distribute PharmaJet’s Tropis^® and Stratis^® needle-free devices across more than 120 markets worldwide. Tropis^® (ID) and Stratis^® (IM/SC) devices are both optimized for vaccine immunizations.

Details

Vaccibody moving forward with Cancer Neoantigen Vaccine Trial

GOLDEN, Colo. — April 17, 2018 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that Vaccibody AS has received approval to start their cancer neoantigen trial using the PharmaJet Stratis® needle-free injection system.

Details

PharmaJet to present latest Research Results at World Vaccine Congress

GOLDEN, Colo. — March 27, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced plans to present their latest research results at the World Vaccine Congress on April 5, in Washington DC at the Renaissance Washington DC Downtown Hotel. The presentation, entitled Expanding Vaccine Effectiveness with Needle-free Delivery, will be presented by Dr. Erin Spiegel, Director of Scientific Affairs at PharmaJet, Inc.

Details

Phase 1 clinical trial for Hantavirus vaccines yields positive interim results

GOLDEN, Colo. — March 13, 2018 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced the reporting of positive interim results from the Phase 1 clinical trial conducted by the US Army Medical Research Institute of Infectious Diseases (USAMRIID). The clinical trial is evaluating two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome (HFRS), using the PharmaJet Stratis® needle-free injection system.

Details

PharmaJet and Genexine collaborate on DNA vaccine development

GOLDEN, Colo. — Feb. 20, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced a global license agreement with Genexine, a leading biotherapeutics company headquartered in South Korea, for the development and commercialization of DNA vaccines for human applications using the PharmaJet needle-free injection systems.

Details

Vaccibody Expands Human Clinical Trial of HPV Vaccine

GOLDEN, Colo. — Feb. 6, 2018 — PharmaJet, the maker of innovative, needle-free injection technology, today announced that Vaccibody AS is expanding their human clinical trial (phase IIa) for the study of a vaccine to treat HPV disease using the PharmaJet Stratis® needle-free injection system.

Details

Study shows superiority of PharmaJet Needle-free Injector for poliovirus vaccine administration

GOLDEN, Colo. — Jan. 23, 2018 — PharmaJet® Inc., the maker of innovative, needle-free injection technology, announced that a study was published in Heliyon Journal showing PharmaJet needle-free injection is superior to needle and syringe for fractional dose poliovirus vaccine campaigns.

Details

Zika Virus vaccine shows significantly higher immune response with Needle-free delivery

GOLDEN, Colo. — Jan. 9, 2018 — PharmaJet, the maker of innovative, needle-free injection technology announced that a recently published study in The Lancet demonstrated that delivery of a Zika virus vaccine with the PharmaJet Stratis^® Needle-free Jet injector produced a significantly higher immune response, as compared with administration via needle and syringe.

Details

PharmaJet and Invectys partner in phase II clinical trial of DNA Cancer Vaccine

GOLDEN, Colo. — Dec. 19, 2017 — PharmaJet, the maker of innovative, needle-free injection technology, announced that Invectys, a French-based biopharmaceutical company, received US FDA approval to proceed with a phase II clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system.

Details